A Phase 2, Long-Term Immunogenicity Follow-up Trial of Adult and Elderly Subjects Who Have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs TAK 214 (Primary)
- Indications Norovirus infections
- Focus Pharmacodynamics
- Sponsors Takeda
- 22 Mar 2017 Planned End Date changed from 1 Dec 2023 to 30 Dec 2023.
- 22 Mar 2017 Planned primary completion date changed from 1 Dec 2023 to 30 Dec 2023.
- 22 Mar 2017 Status changed from not yet recruiting to recruiting.